688298 Zhejiang Orient Gene BiotechWatchlist
About Zhejiang Orient Gene Biotech Company
The company was founded in December 2005. It has all kinds of plants, GMP workshops, office buildings and auxiliary buildings, and has all kinds of imported and domestically produced advanced equipment. The company is a national high-tech enterprise specializing in the development, production and sale of rapid in vitro diagnostic reagents, the Zhejiang Postdoctoral Research Workstation and the Huzhou Academician Expert Workstation. The company specializes in R&D, production and sales of in vitro diagnostic products. The company's core technology is mainly based on independent research and development, including POCT rapid diagnosis platforms (immune diagnosis platform, biomaterial platform, in vitro diagnostic instrument platform, biochemical diagnosis platform), molecular diagnosis platform, and liquid biochip platform. Corporate honors: academician workstations, high-tech enterprise certification, high-tech enterprise certificates, etc.
[Instant Analysis of BT Financial Report] Oriental Biotech 2023 Interim Report Analysis: Facing challenges, responding positively, business conditions to be seen
Oriental Biology (stock code: 688298) is a company focusing on the in vitro diagnosis industry. Its industry is the in vitro diagnosis industry under the medical device industry. In vitro diagnostic products mainly include diagnostic equipment and diagnostic reagents, among which diagnostic reagents dominate the entire industry. The size of the global in vitro diagnostic market continues to grow, and is expected to grow at a compound annual growth rate of around 6% in the future. As a member of the in vitro diagnostic industry, Dongfang Biotech is expected to benefit from the development trend of the industry. However, according to Dongfang Biotech's 2023 interim report, the company faced a sales business that basically removed COVID-19 testing products during this reporting period, resulting in
A Look At The Fair Value Of Zhejiang Orient Gene Biotech Co., Ltd. (SHSE:688298)
Key Insights The projected fair value for Zhejiang Orient Gene Biotech is CN¥34.32 based on Dividend Discount Model Current share price of CN¥37.44 suggests Zhejiang Orient Gene Biotech is potential
Does Zhejiang Orient Gene Biotech (SHSE:688298) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor